An oral drug raised growth speed in children with achondroplasia in a phase 3 trial

Children with achondroplasia who took a once-daily pill, infigratinib, grew about 1.74 cm per year faster than children on placebo over 52 weeks, in a phase 3 trial published in the New England Journal of Medicine [s1]. The result is notable because infigratinib is taken orally, where the first approved drug for the condition is a daily injection — but the trial measured growth speed over one year, not the long-term health complications that define achondroplasia.

What the trial shows, precisely, is a faster growth rate on a surrogate measure. What it does not yet show is whether that translates into a healthier life.

The condition and why the drug was tried

Achondroplasia is the most common genetic cause of short-limbed short stature, driven by gain-of-function variants in the gene FGFR3 that throttle bone growth at the growth plate [s1]. Its burden is not only height: affected children face risks from spinal-canal narrowing, compression at the base of the skull and other complications.

Infigratinib is an oral inhibitor of FGFR1–3 tyrosine kinases — it dials down the over-active pathway that the FGFR3 variant drives [s1]. The same molecule is already used in oncology. Here it was repurposed, at a low dose, to act on the biology of the growth plate.

The trial

PROPEL 3 was a phase 3, multicentre, double-blind, placebo-controlled trial [s1]. It randomly assigned children with achondroplasia aged 3 to 17 years, in a 2:1 ratio, to infigratinib at 0.25 mg per kilogram of body weight or to placebo, taken once daily for 52 weeks [s1]. The primary endpoint was the change from baseline in annualised height velocity — how fast a child grew over the year — in the infigratinib group compared with placebo at week 52 [s1].

In all, 114 children underwent randomisation: 75 to infigratinib (with one withdrawal before treatment) and 39 to placebo [s1].

The results

For the primary endpoint, the difference between infigratinib and placebo in the least-squares mean change from baseline was 1.74 cm per year (95% CI, 1.31 to 2.17; P<0.001) [s1]. On the key secondary endpoints, the between-group difference in height z-score was 0.32 (96% CI, 0.23 to 0.41; P<0.001), and the difference in the upper-to-lower body-segment ratio — a measure of body proportionality — was −0.02 (96% CI, −0.06 to 0.01) [s1].

On safety, adverse events occurred in 71 of 74 children (96%) in the infigratinib group and 37 of 39 (95%) on placebo [s1]. Serious adverse events occurred in 4 of 74 (5%) and 1 of 39 (3%), respectively, and none of the serious events or any adverse event leading to discontinuation was judged by investigators to be related to infigratinib or placebo [s1].

The caveats that matter most

Growth velocity is a surrogate. The trial measured how fast children grew over one year, not final adult height and not the medical complications of achondroplasia. The segment-ratio endpoint, a proxy for whether growth is proportionate, showed a confidence interval that crossed zero [s1]. Faster growth is the mechanism; whether it prevents spinal or neurological complications is unanswered here.

Fifty-two weeks is short for a lifelong condition. Durability of the growth effect, and whether it accumulates into meaningful adult height or fades, cannot be read from a one-year trial.

The comparison is against placebo, not the existing drug. Infigratinib was not tested head-to-head against the approved injectable therapy, so claims that an oral option is "as good" are not supported by this trial.

The funder is the manufacturer. The trial was funded by BridgeBio Pharma [s1]. That does not invalidate a double-blind, placebo-controlled result, but the company's framing and the trial's evidence should be kept distinct.

Where it sits

An accompanying editorial, titled "Infigratinib in Achondroplasia — A Potentially Giant Step Forward," signals cautious optimism while the word "potentially" carries the hedge [s2]. The site has separately covered vosoritide in hypochondroplasia, a related FGFR3-pathway skeletal condition, where similar questions about growth-velocity endpoints apply.

The pill-versus-injection distinction is real and matters to families, but it is a question of convenience and adherence, not of proven superiority on health outcomes.

What to watch

Longer-term follow-up on adult height and on the complications that drive morbidity in achondroplasia; any head-to-head data against injectable therapy; and how regulators weigh a growth-velocity endpoint when the condition's burden is only partly about height. PROPEL 3 is registered as NCT06164951 [s1].

This article describes trial results, including a dose, for informational purposes only. It is not medical advice and not a recommendation about any medication.